Try our mobile app

Switch to company model in classical logic    *

General information

Country: ISRAEL

Sector: Biotechnology

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm`s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Website: mediwound.com



Growth: Good revenue growth rate 100.0%, there is acceleration compared to average historical growth rates 60.2%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -55.6%. On average the margin is decreasing steadily. Gross margin is normal, +23.8%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 0% of quarters (showing a gain of -$0.25 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -5.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 183.1% higher than minimum and 8.6% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.3x by EV / Sales multiple , the company can be 43.2% overvalued

Key Financials (Download financials)

Ticker: MDWD
Share price, USD:  (-2.5%)20.33
year average price 18.09  


year start price 19.80 2024-07-27

min close price 14.97 2025-04-04

max close price 22.24 2025-06-02

current price 20.33 2025-07-26
Common stocks: 5 819 310

Dividend Yield:  0.0%
EV / Sales: 4.0x
Margin (EBITDA LTM / Revenue): -55.6%
Fundamental value created in LTM:
Market Cap ($m): 118
Net Debt ($m): -9
EV (Enterprise Value): 109
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-21zacks.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

2025-03-19seekingalpha.com

MediWound Ltd. (MDWD) Q4 2024 Earnings Call Transcript

2025-03-19zacks.com

MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates

2025-02-12reuters.com

MediWound to launch Phase III trial for venous leg ulcers

2024-11-26seekingalpha.com

MediWound Ltd. (MDWD) Q3 2024 Earnings Call Transcript

2024-11-26zacks.com

MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates

2024-11-26globenewswire.com

MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update

2024-10-29seekingalpha.com

MediWound Is A Healthy Investment

2024-08-15globenewswire.com

MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns

2024-08-14seekingalpha.com

MediWound Ltd. (MDWD) Q2 2024 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-26 2024-08-14 2024-03-21 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-12-31 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 07:05:16 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2022-12-31 00:00:00 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 4M 5M 5M 5M 5M 5M 4M 12M 6M 5M 4M
costOfRevenue 4M 5M 4M 5M 4M 4M 3M 3M 3M 4M 3M
grossProfit 677 000 447 000 607 000 719 000 896 000 1M 826 000 8M 2M 1M 1M
grossProfitRatio 0.155 0.088 0.122 0.135 0.188 0.238 0.217 0.702 0.419 0.238 0.331
researchAndDevelopmentExpenses 3M 2M 1M 2M 2M 2M 2M 3M 3M 2M 2M
generalAndAdministrativeExpenses 2M 2M 2M 7M 0 0 0 648 000 3M 1M 0
sellingAndMarketingExpenses 1M 1M 1M 5M 0 0 0 2M 0 935 000 0
sellingGeneralAndAdministrativeExpenses 3M 3M 3M 3M 3M 3M 3M 3M 3M 2M 2M
otherExpenses 0 0 0 0 0 0 0 958 000 0 0 0
operatingExpenses 6M 5M 4M 5M 4M 5M 5M 6M 6M 4M 5M
costAndExpenses 9M 10M 9M 9M 8M 9M 8M 10M 9M 8M 8M
interestIncome 0 582 000 0 2M 877 000 6M 676 000 -11 000 0 11 000
interestExpense 0 2M 6M 0 0 893 000 -676 000 -2M 684 000 687 000 301 000
depreciationAndAmortization 361 000 357 000 368 000 346 000 339 000 315 000 303 000 -11M 338 000 329 000 321 000
ebitda -5M -4M -3M -4M -3M -4M -4M -9M -3M -3M -3M
ebitdaratio -1.084 -0.815 -0.678 -0.662 -0.562 -0.774 -1.069 -0.755 -0.547 -0.714 -0.672
operatingIncome -5M -4M -4M -4M -3M -4M -4M 2M -4M -3M -3M
operatingIncomeRatio -1.167 -0.886 -0.752 -0.727 -0.633 -0.84 -1.149 0.156 -0.605 -0.721 -0.745
totalOtherIncomeExpensesNet -5M -2M -6M 2M 877 000 5M 676 000 -9M -684 000 -985 000 -301 000
incomeBeforeTax -10M -6M -10M -2M -2M 928 000 -4M -7M -4M -4M -4M
incomeBeforeTaxRatio -2.356 -1.246 -1.955 -0.304 -0.45 0.194 -0.971 -0.636 -0.723 -0.932 -0.813
incomeTaxExpense 21 000 -2000 24 000 120 000 48 000 12 000 5000 65 000 5000 4000 4000
netIncome -10M -6M -10M -2M -2M 916 000 -4M -7M -4M -4M -4M
netIncomeRatio -2.361 -1.245 -1.96 -0.327 -0.46 0.192 -0.972 -0.642 -0.724 -0.933 -0.814
eps -0.98 -0.68 -1.05 -0.19 -0.24 0.1 -0.44 -1.18 -0.88 -0.91 -0.018
epsdiluted -0.98 -0.68 -1.05 -0.19 -0.24 0.1 -0.44 -1.18 -0.88 -0.91 -0.018
weightedAverageShsOut 11M 9M 9M 9M 9M 9M 8M 6M 5M 5M 201M
weightedAverageShsOutDil 11M 9M 9M 9M 9M 9M 8M 6M 5M 5M 201M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-26 2024-08-14 2024-03-21 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-12-31 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 07:05:16 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2022-12-31 00:00:00 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 0 4M 36M 12M 9M 51M 51M 34M 0 8M 0
shortTermInvestments 0 25M 0 30M 36M 32M 6M 0 0 3M 0
cashAndShortTermInvestments 46M 29M 36M 42M 46M 51M 57M 34M 18M 10M 17M
netReceivables 5M 5M 5M 4M 4M 4M 4M 10M 5M 4M 3M
inventory 3M 3M 3M 3M 4M 3M 3M 2M 2M 2M 2M
otherCurrentAssets 0 0 0 722 000 0 0 0 10M 0 168 000 0
totalCurrentAssets 54M 37M 44M 50M 53M 58M 63M 46M 24M 17M 22M
propertyPlantEquipmentNet 20M 19M 17M 16M 13M 6M 5M 4M 4M 4M 4M
goodwill 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 132 000 149 000 165 000 182 000 198 000 0 231 000 0 0 0
goodwillAndIntangibleAssets 116 000 132 000 149 000 165 000 182 000 198 000 215 000 231 000 248 000 264 000 281 000
longTermInvestments 0 238 000 238 000 490 000 483 000 277 000 0 0 0 0 0
taxAssets 0 0 0 0 -483 000 -277 000 0 0 0 0 0
otherNonCurrentAssets 484 000 453 000 446 000 183 000 483 000 -6M 305 000 364 000 230 000 230 000 230 000
totalNonCurrentAssets 21M 20M 18M 17M 14M 6M 5M 4M 4M 4M 4M
otherAssets 0 0 0 0 0 0 0 0 0 0 0
totalAssets 75M 57M 62M 66M 67M 64M 69M 50M 29M 21M 26M
accountPayables 3M 3M 4M 6M 4M 4M 3M 6M 4M 5M 6M
shortTermDebt 0 0 2M 361 000 0 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 1 24 000 0 0 0 63 000 0 0 0
otherCurrentLiabilities 22M 20M 17M 5M 5M 5M 6M 6M 5M 6M 6M
totalCurrentLiabilities 26M 23M 22M 11M 8M 8M 9M 12M 9M 10M 11M
longTermDebt 6M 6M 6M 6M 6M 677 000 743 000 846 000 952 000 1M 1M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 31 000 61 000 91 000
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 8M 10M 3M 10M 20M 20M 25M 26M 14M 12M 12M
totalNonCurrentLiabilities 15M 17M 9M 16M 26M 21M 26M 27M 18M 13M 13M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 6M 6M 6M 6M 6M 677 000 743 000 846 000 952 000 1M 1M
totalLiabilities 40M 39M 31M 27M 34M 29M 35M 39M 27M 23M 24M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 0 186 000 23M 184 000 33M 184 000 0 143 000 0 93 000 0
retainedEarnings 0 -191M 0 -175M 0 -171M 0 -168M 0 -156M 0
accumulatedOtherComprehensiveIncomeLoss 0 -8000 0 -18 000 0 -14 000 0 -5000 0 3000 0
othertotalStockholdersEquity 34M 209M 0 206M 0 206M 0 179M 2M 0 2M
totalStockholdersEquity 34M 18M 23M 32M 33M 35M 33M 11M 2M -2M 2M
totalEquity 34M 18M 23M 32M 33M 35M 33M 11M 2M -2M 2M
totalLiabilitiesAndStockholdersEquity 75M 57M 62M 66M 67M 64M 69M 50M 29M 21M 26M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 75M 57M 62M 66M 67M 64M 69M 50M 29M 21M 26M
totalInvestments 0 26M 238 000 30M 36M 32M 6M 0 0 0 0
totalDebt 6M 6M 8M 7M 6M 677 000 743 000 846 000 952 000 1M 1M
netDebt 6M 4M -28M -5M -3M -50M -50M -33M 952 000 -7M 1M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2 2022 q1
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31
symbol MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD MDWD
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-26 2024-08-14 2024-03-21 2024-03-21 2023-11-21 2023-08-15 2023-03-16 2022-12-31 2022-09-30 2022-06-30 2022-03-31
acceptedDate 2024-11-26 07:05:06 2024-08-14 07:07:45 2024-03-21 07:05:16 2024-03-21 07:05:16 2023-11-21 07:05:10 2023-08-15 16:10:35 2023-03-16 07:15:08 2022-12-31 00:00:00 2022-09-29 20:00:00 2022-06-30 2022-03-30 20:00:00
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome -10M -6M -10M -2M -2M 916 000 -4M -7M -4M -4M -4M
depreciationAndAmortization 361 000 357 000 368 000 346 000 339 000 315 000 303 000 284 000 338 000 329 000 321 000
deferredIncomeTax 0 0 0 -373 772 -701 000 -5M 0 0 0 0 0
stockBasedCompensation 1M 758 000 512 000 298 000 311 000 712 000 619 000 642 000 707 000 252 000 345 000
changeInWorkingCapital 98 000 -295 606 -2M 940 451 -539 000 -2M 4M -1M -2M -2M -2M
accountsReceivables -177 000 416 284 -238 000 -1M 71 000 -707 000 7M -5M -421 000 -1M -579 000
inventory 184 000 103 000 -448 000 798 126 -526 000 -579 000 -583 000 -113 000 139 000 -37 000 -710 000
accountsPayables -48 000 -522 405 -1M 1M -51 000 312 000 -2M 2M -1M -272 000 283 000
otherWorkingCapital 139 000 -292 485 260 000 324 223 -33 000 -924 000 -480 000 2M -646 000 0 0
otherNonCashItems 5M 2M 10M -1M -465 000 -416 000 -388 000 10M 759 000 552 000 622 000
netCashProvidedByOperatingActivities -4M -4M -4M -2M -3M -5M 652 000 2M -5M -5M -4M
investmentsInPropertyPlantAndEquipment -1M -3M -1M -2M -2M -1M -2M -174 000 -83 000 -138 000 -160 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments -14M 0 -1M 7M -5M -26M 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 2M 0 0 0
otherInvestingActivites 461 000 6M -525 000 -1 361 874 805 407 -6M 71 000 3000 -2M 0
netCashUsedForInvestingActivites -14M 3M -2M 5M -6M -26M -7M 2M -80 000 -3M -160 000
debtRepayment -228 000 -214 000 -244 000 -204 000 -240 000 -157 000 -177 000 -170 000 -181 000 -172 000 -178 000
commonStockIssued 22M -499 000 499 000 -298 773 -11 204 -69 256 25M -10M 0 0 10M
commonStockRepurchased 0 0 0 0 0 0 0 556 000 0 -556 000 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -1M 111 000 -954 000 14 561 -487 000 -178 744 -727 000 25M 12M 0 -162 000
netCashUsedProvidedByFinancingActivities 21M -103 000 -699 000 -204 000 -727 000 -405 000 24M 15M 12M -728 000 10M
effectOfForexChangesOnCash 18 000 -15 000 -89 000 378 000 -81 000 -120 000 -337 000 -44 000 45 000 -303 000 -247 000
netChangeInCash 3M -896 000 24M 3M -10M -32M 17M 19M 7M -9M 6M
cashAtEndOfPeriod 6M 4M 36M 12M 9M 19M 51M 34M 15M 8M 17M
cashAtBeginningOfPeriod 4M 5M 12M 9M 19M 51M 34M 15M 8M 17M 11M
operatingCashFlow -4M -4M -4M -2M -3M -5M 652 000 2M -5M -5M -4M
capitalExpenditure -1M -3M -1M -2M -2M -1M -2M -174 000 -83 000 -138 000 -160 000
freeCashFlow -5M -7M -5M -4M -5M -6M -853 000 2M -5M -5M -4M
link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-26 ET (fiscal 2024 q3)
2024 q2
2024-08-14 ET (fiscal 2024 q2)
2024 q1
2024-05-29 ET (fiscal 2024 q1)
2023 q4
2024-03-21 ET (fiscal 2023 q4)
2023 q3
2023-11-21 ET (fiscal 2023 q3)
2023 q2
2023-08-16 ET (fiscal 2023 q2)
2023 q1
2023-05-30 ET (fiscal 2023 q1)
2022 q4
2023-03-16 ET (fiscal 2022 q4)
2022 q3
2022-11-15 ET (fiscal 2022 q3)
2022 q2
2022-08-10 ET (fiscal 2022 q2)
2022 q1
2022-05-17 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-12 13:00 ET
MediWound to Report Third Quarter 2024 Financial Results
2024-10-10 11:00 ET
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
2024-10-08 12:00 ET
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
2024-09-03 12:00 ET
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-15 20:15 ET
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
2024-08-14 11:00 ET
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
2024-08-05 11:30 ET
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
2024-08-02 12:00 ET
MediWound to Report Second Quarter 2024 Financial Results
2024-07-29 12:00 ET
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
2024-07-16 11:30 ET
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
2024-07-15 11:32 ET
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd
2024-07-15 11:00 ET
MediWound Announces $25 Million Strategic Private Placement Financing
2024-05-29 11:00 ET
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
2024-05-22 12:00 ET
MediWound to Report First Quarter 2024 Financial Results
2024-04-25 12:00 ET
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
2024-03-21 11:00 ET
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
2024-03-14 12:00 ET
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
2024-02-12 12:00 ET
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
2024-02-05 13:00 ET
MediWound to Participate in Two Upcoming Investor Conferences
2024-01-09 12:00 ET
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
2023-12-28 12:00 ET
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
2023-12-21 13:00 ET
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
2023-11-21 12:02 ET
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
2023-11-21 12:00 ET
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
2023-11-14 13:02 ET
MediWound to Report Third Quarter 2023 Financial Results
2023-11-13 12:00 ET
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
2023-11-08 12:00 ET
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
2023-10-11 10:00 ET
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
2023-10-09 11:34 ET
MediWound Deploys NexoBrid® for Emergency Supply
2023-09-26 11:00 ET
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
2023-09-21 10:00 ET
MediWound Announces U.S. Commercial Availability of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
2023-09-11 12:00 ET
MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress
2023-09-05 12:00 ET
MediWound to Participate in Fireside Chat at H.C. Wainwright 25th Annual Global Investment Conference
2023-08-15 20:03 ET
MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update
2023-08-15 20:02 ET
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
2023-08-07 12:00 ET
MediWound to Report Second Quarter 2023 Financial Results
2023-08-01 11:30 ET
MediWound Announces Commercial Launch of NexoBrid® in Japan
2023-07-10 11:30 ET
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2023-07-03 11:00 ET
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
2023-06-14 12:00 ET
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
2023-05-30 11:00 ET
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
2023-05-12 12:00 ET
MediWound to Report First Quarter 2023 Financial Results
2023-05-09 11:30 ET
MediWound Announces an Additional $10 Million Award from BARDA
2023-04-26 12:00 ET
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
2023-03-16 11:10 ET
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
2023-03-16 11:00 ET
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
2023-03-06 12:00 ET
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
2023-03-02 13:47 ET
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
2023-02-23 13:00 ET
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
2023-02-07 21:01 ET
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
2023-02-03 15:30 ET
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
2022-12-23 13:00 ET
MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
2022-12-20 13:00 ET
MediWound Strengthens European Presence of NexoBrid®
2022-12-19 12:00 ET
MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2022-12-13 10:30 ET
MediWound Expands Global Presence as NexoBrid® Gains Approval in India
2022-12-05 21:05 ET
MediWound Announces a 1-for-7 Reverse Share Split
2022-11-15 12:00 ET
MediWound Reports Third Quarter 2022 Financial Results and Provides Company Update
2022-11-09 13:00 ET
MediWound’s EscharEx Featured in Paper as a Potential Paradigm Shift Towards Non-Surgical Wound Bed Preparation in DFUs
2022-11-03 12:00 ET
MediWound to Report Third Quarter 2022 Financial Results
2022-10-25 11:00 ET
MediWound Announces Formation of Strategic Advisory Board
2022-10-18 11:00 ET
MediWound's EscharEx® Featured in Oral and Poster Presentations at the Symposium on Advanced Wound Care (SAWC) Fall 2022
2022-10-07 10:00 ET
MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings
2022-09-22 12:02 ET
MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million
2022-09-20 11:00 ET
EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns
2022-09-12 12:00 ET
MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress
2022-08-09 11:30 ET
MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
2022-08-08 20:05 ET
MediWound Enhances Its Board and Executive Leadership Team
2022-08-01 12:00 ET
MediWound Schedules Second Quarter 2022 Financial Results
2022-07-11 11:00 ET
MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2022-07-08 12:00 ET
MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
2022-07-07 11:00 ET
MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
2022-07-05 20:05 ET
MediWound to Host a Key Opinion Leader Investor Day on EscharEx
2022-06-30 11:00 ET
MediWound Names Mr. Tzvi Palash as Chief Operating Officer
2022-05-17 11:01 ET
MediWound Announces CEO Transition
2022-05-17 11:00 ET
MediWound Reports First Quarter 2022 Financial Results
2022-05-12 11:00 ET
MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
2022-05-10 20:01 ET
MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022
2022-04-12 12:00 ET
MediWound's EscharEx Highlighted in Poster and Oral Presentation at the Symposium on Advanced Wound Care (SAWC) Spring 2022
2022-03-29 12:00 ET
MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022
2022-03-22 20:05 ET
MediWound Announces Exercise of Over-Allotment Option
2022-03-21 11:30 ET
MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds
2022-03-17 11:00 ET
MediWound Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-10 22:05 ET
MediWound Announces Closing of Public Offering of Ordinary Shares
2022-03-10 13:00 ET
MediWound to Report Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call and Webcast on March 17, 2022
2022-03-03 13:30 ET
MediWound Announces Pricing of Public Offering of Ordinary Shares
2022-03-02 21:24 ET
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
2022-03-01 13:00 ET
MediWound to Present at Upcoming Investor Conferences in March
2022-02-17 11:00 ET
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
2022-02-14 14:02 ET
MediWound to Present at Upcoming Investor Conferences in February
2022-02-10 12:00 ET
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
2022-01-24 11:00 ET
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
2021-12-20 12:00 ET
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
2021-12-06 12:00 ET
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
2021-11-18 12:30 ET
EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
2021-11-16 12:00 ET
MediWound Reports Third Quarter 2021 Financial Results
2021-11-04 12:00 ET
MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021
2021-10-04 11:30 ET
MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care
2021-09-03 20:14 ET
MediWound to Present at Upcoming Investor Conferences
2021-08-10 11:00 ET
MediWound Reports Second Quarter Financial Results
2021-08-02 20:05 ET
MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021
2021-07-28 11:00 ET
MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study
2021-07-26 11:00 ET
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
2021-07-20 11:00 ET
MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns
2021-07-09 12:00 ET
MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal
2021-06-09 20:30 ET
MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study
2021-06-07 11:00 ET
MediWound Announces Peer-Reviewed Paper of a Case Series Report of Basal Cell Carcinoma Published in the Open Dermatology Journal
2021-05-05 11:00 ET
MediWound Reports First Quarter 2021 Financial Results
2021-04-26 20:20 ET
MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021
2021-04-22 11:30 ET
MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx
2021-03-24 20:05 ET
MediWound Hosting Analyst Day Webinar on EscharEx – Enzymatic Debridement Agent for Chronic Wounds
2021-02-25 21:01 ET
MediWound to Participate in Upcoming March Investment Conferences
2021-02-25 12:00 ET
MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
2021-02-22 11:30 ET
MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer
2021-02-16 21:05 ET
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
2021-02-10 21:15 ET
MediWound to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-01-11 12:00 ET
MediWound Provides Progress Update on Its EscharEx Clinical Development Program
2021-01-05 12:00 ET
MediWound to Participate in Upcoming Investor Conferences in January
2020-12-21 12:30 ET
Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
2020-12-14 21:15 ET
MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
2020-11-10 12:00 ET
MediWound Reports Third Quarter 2020 Financial Results
2020-11-02 21:01 ET
MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
2020-10-28 11:00 ET
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
2020-10-14 12:00 ET
MediWound Studying the Effect of EscharEx on Biofilm Burden
2020-09-03 13:00 ET
MediWound to Present at Upcoming Investor Conferences in September
2020-08-06 11:00 ET
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-28 12:00 ET
MediWound to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
2020-06-30 11:00 ET
MediWound Announces Submission of Biologics License Application to the U.S. FDA for NexoBrid for the Treatment of Severe Thermal Burns
2020-05-20 11:00 ET
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-13 12:00 ET
MediWound to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 20, 2020
2020-05-04 11:30 ET
MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements
2020-04-27 11:00 ET
MediWound Strengthens Board of Directors
2020-03-30 11:30 ET
MediWound Provides Corporate Update Related to COVID-19 Pandemic
2020-03-03 11:00 ET
BARDA Upsizes its Contract with MediWound Awarding an Additional $5.5 Million for Emergency Readiness for NexoBrid Deployment
2020-02-28 21:18 ET
MediWound to Present at Cowen and Company 40th Annual Healthcare Conference
2020-02-25 12:00 ET
MediWound Reports Fourth Quarter and Full-Year 2019 Financial Results
2020-02-18 13:00 ET
MediWound to Report Fourth Quarter & Fiscal 2019 Financial Results and Host a Conference Call and Webcast on February 25, 2020
2020-01-13 13:00 ET
MediWound Expands its Distribution Agreement with GENFA MEDICA SA to Market NexoBrid in Ukraine and the Baltic States
2020-01-06 11:30 ET
BARDA Initiates the Procurement of NexoBrid for Emergency Response
2020-01-02 12:30 ET
MediWound Continues NexoBrid’s Global Expansion Through a New Distribution Agreement in Australia, New Zealand and Singapore with Balance Medical
2019-12-03 12:30 ET
MediWound Initiates U.S. Phase 2 Adaptive Design Study of EscharEx® for Treatment of Venous Leg Ulcers
2019-11-14 12:00 ET
MediWound Reports Third Quarter 2019 Financial Results
2019-11-06 13:00 ET
MediWound to Report Third Quarter 2019 Financial Results and Host a Conference Call and Webcast on November 14
2019-03-12 11:00 ET
MediWound Announces Executive Leadership Changes
2019-01-22 11:30 ET
MediWound Announces Positive Top-Line Results from Its Pivotal Phase 3 Study (DETECT) in NexoBrid® for Eschar Removal of Severe Thermal Burns

SEC forms

Show financial reports only

SEC form 6
2025-05-21 11:07 ET
MediWound published news for 2025 q1
SEC form 6
2025-05-21 11:07 ET
MediWound reported for 2025 q1
SEC form 6
2025-05-15 20:35 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 6
2025-04-07 20:04 ET
MediWound published news for 2025 q1
SEC form 6
2025-03-19 11:05 ET
MediWound published news for 2024 q4
SEC form 6
2025-03-19 11:05 ET
MediWound reported for 2024 q4
SEC form 6
2025-02-12 12:05 ET
MediWound published news for 2024 q4
SEC form 6
2025-02-12 12:05 ET
MediWound published news for 2024 q4
SEC form 6
2024-11-26 07:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-26 07:05 ET
MediWound reported for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-11-14 16:05 ET
MediWound published news for 2024 q3
SEC form 6
2024-08-15 16:20 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-15 16:20 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:21 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:21 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-14 07:07 ET
MediWound reported for 2024 q2
SEC form 6
2024-08-05 08:53 ET
MediWound published news for 2024 q2
SEC form 6
2024-08-05 08:53 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-16 07:35 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-16 07:35 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-15 07:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-07-09 16:05 ET
MediWound published news for 2024 q2
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 16:01 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 07:05 ET
MediWound published news for 2024 q1
SEC form 6
2024-05-29 07:05 ET
MediWound reported for 2024 q1
SEC form 6
2024-03-21 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-03-21 07:05 ET
MediWound reported for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-02-12 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-09 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-09 07:05 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-08 07:00 ET
MediWound published news for 2023 q4
SEC form 6
2024-01-08 07:00 ET
MediWound published news for 2023 q4
SEC form 6
2023-12-28 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-12-28 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-11-21 07:05 ET
MediWound reported for 2023 q3
SEC form 6
2023-11-21 07:03 ET
MediWound published news for 2023 q3
SEC form 6
2023-11-13 07:05 ET
MediWound published news for 2023 q3
SEC form 6
2023-09-26 16:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-09-21 06:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-08-15 16:10 ET
MediWound reported for 2023 q2
SEC form 6
2023-08-15 16:01 ET
MediWound published news for 2023 q2
SEC form 6
2023-08-02 08:00 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-17 16:01 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-10 07:35 ET
MediWound published news for 2023 q2
SEC form 6
2023-07-03 07:05 ET
MediWound published news for 2023 q2
SEC form 6
2023-05-31 16:10 ET
MediWound published news for 2023 q1
SEC form 6
2023-05-31 16:05 ET
MediWound published news for 2023 q1
SEC form 6
2023-05-30 07:05 ET
MediWound reported for 2023 q1
SEC form 6
2023-05-09 07:35 ET
MediWound published news for 2023 q1
SEC form 6
2023-04-20 16:06 ET
MediWound published news for 2023 q1
SEC form 6
2023-03-16 07:15 ET
MediWound reported for 2022 q4
SEC form 6
2023-03-16 07:05 ET
MediWound reported for 2022 q4
SEC form 6
2023-03-16 07:02 ET
MediWound published news for 2022 q4
SEC form 6
2023-02-13 08:00 ET
MediWound published news for 2022 q4
SEC form 6
2023-02-07 16:06 ET
MediWound published news for 2022 q4
SEC form 6
2023-01-09 06:09 ET
MediWound published news for 2022 q4
SEC form 6
2022-12-29 13:52 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-23 08:10 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-20 07:01 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-19 07:28 ET
MediWound published news for 2022 q3
SEC form 6
2022-12-05 16:10 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-28 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-15 07:05 ET
MediWound reported for 2022 q3
SEC form 6
2022-11-14 16:06 ET
MediWound published news for 2022 q3
SEC form 6
2022-11-09 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-10-21 16:05 ET
MediWound published news for 2022 q3
SEC form 6
2022-09-26 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-09-20 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-09 00:00 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-08 16:10 ET
MediWound published news for 2022 q2
SEC form 6
2022-08-03 07:35 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-19 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-12 16:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-11 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-07-07 07:05 ET
MediWound published news for 2022 q2
SEC form 6
2022-06-30 07:05 ET
MediWound published news for 2022 q1
SEC form 6
2022-06-09 07:04 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-17 07:06 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-17 07:05 ET
MediWound published news for 2022 q1
SEC form 6
2022-05-12 07:04 ET
MediWound published news for 2022 q1
SEC form 6
2022-03-22 16:10 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-17 07:08 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-17 07:05 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-03 16:09 ET
MediWound published news for 2021 q4
SEC form 6
2022-03-02 16:33 ET
MediWound published news for 2021 q4
SEC form 6
2022-02-10 07:05 ET
MediWound published news for 2021 q4
SEC form 6
2022-01-24 06:05 ET
MediWound published news for 2021 q4
SEC form 6
2021-12-20 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-12-06 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-11-16 07:05 ET
MediWound published news for 2021 q3
SEC form 6
2021-08-10 00:00 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-28 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-26 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-07-20 07:05 ET
MediWound published news for 2021 q2
SEC form 6
2021-06-29 08:54 ET
MediWound published news for 2021 q1
SEC form 6
2021-06-15 16:06 ET
MediWound published news for 2021 q1
SEC form 6
2021-05-05 16:15 ET
MediWound published news for 2021 q1
SEC form 6
2021-05-05 07:05 ET
MediWound published news for 2021 q1
SEC form 6
2021-04-22 07:39 ET
MediWound published news for 2021 q1
SEC form 6
2021-02-25 07:53 ET
MediWound published news for 2020 q4
SEC form 6
2021-02-25 07:05 ET
MediWound published news for 2020 q4
SEC form 6
2021-02-22 06:30 ET
MediWound published news for 2020 q4
SEC form 6
2021-01-11 07:05 ET
MediWound published news for 2020 q4
SEC form 6
2020-11-10 07:06 ET
MediWound published news for 2020 q3
SEC form 6
2020-10-30 16:30 ET
MediWound published news for 2020 q3
SEC form 6
2020-10-28 07:00 ET
MediWound published news for 2020 q3